By Catherine Eckford (European Pharmaceutical Review)2024-04-17T15:11:27
EU approval for Roche’s subcutaneous OCREVUS is anticipated mid-2024, depending on acceptance of regulatory submission.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-14T12:32:00Z
Sponsored by Thermo Fisher Scientific
2026-04-14T12:29:00Z
Sponsored by JRS Pharma, In association with Vetter Pharma
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-03-26T15:00:00 2026-03-26T16:00:00
Sponsored by Medable
2025-11-20T15:00:00
Sponsored by Rapid Micro Biosystems
2025-06-11T13:00:00
Sponsored by Rapid Micro Biosystems
2025-12-11T13:32:00
Sponsored by Hexagon
2026-04-29T14:00:00 2026-04-29T15:00:00
Sponsored by USP
Site powered by Webvision Cloud